Monoclonal antibodies against cutaneous T-cell lymphomas

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;19(127):2375–2390.
   Web of Science ®Google Scholar
• Kempf W, Kazakov DV, Kerl K. Cutaneous lymphomas: an update. Part 1: T-cell and natural killer/T-cell lymphomas and related conditions. Am J Dermatopathol. 2014;36:105–123.
   PubMed Web of Science ®Google Scholar
• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70:e1–e17.
   PubMed Web of Science ®Google Scholar
• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70:205.e1–16.
   Web of Science ®Google Scholar
• Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34:22–35.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:151–165.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19:2456–2471.
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez-Diez J. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology. 2015;20:538–542.
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:1870–1877.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13:2318–2322.
   PubMed Web of Science ®Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49:386–394.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119:4115–4122.
   PubMed Web of Science ®Google Scholar
• Duvic M, Kim YH, Zinzani PL, et al. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017;23:3552–3556.
   PubMed Web of Science ®Google Scholar
• Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30:4091–4097.
   PubMed Web of Science ®Google Scholar
• Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, et al. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol. 2009;161:660–663.
   PubMed Web of Science ®Google Scholar
• Guenova E, Hoetzenecker W, Rozati S, et al. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs. 2014;23:457–467.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Bonthapally V, Huebner D, et al. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: cutaneous T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:228–240.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Su H, Shen X, et al. The immunological function of CD52 and its targeting in organ transplantation. Inflamm Res. 2017;66:571–578.
   PubMed Web of Science ®Google Scholar
• Fraser G, Smith CA, Imrie K, et al. Alemtuzumab in chronic lymphocytic leukemia. Hematology disease site group of cancer care Ontario’s program in evidence-based care. Curr Oncol. 2007;14:96–109.
   PubMedGoogle Scholar
• Alinari L, Lapalombella R, Andritsos L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26:3644–3653.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:22–34.
   PubMed Web of Science ®Google Scholar
• Sud A, Dearden C. T-cell prolymphocytic leukemia. Hematol Oncol Clin North Am. 2017;31:273–283.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19:S27–32.
   PubMed Web of Science ®Google Scholar
• Capalbo S, Delia M, Dargenio M, et al. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment. Med Oncol. 2003;20:389–396.
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267–4272.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica. 2005;90:702–703.
   PubMed Web of Science ®Google Scholar
• Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92:784–794.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009;50:1969–1976.
   PubMed Web of Science ®Google Scholar
• De Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170:720–724.
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1–14.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157–164.
   PubMed Web of Science ®Google Scholar
• van de Donk NW Dhimolea E. Brentuximab vedotin. MAbs. 2012;4:458–465.
   PubMed Web of Science ®Google Scholar
• Deng C, Pan B, O’Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19:22–27.
   PubMed Web of Science ®Google Scholar
• Dada R, Zekri J, Al Saadi R. Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opin Biol Ther. 2016;16:739–745.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma. Drugs. 2017;77:435–445.
   PubMed Web of Science ®Google Scholar
• Mody K, Wallace JS, Stearns DM, et al. CD30-positive cutaneous T-cell lymphoma and response to Brentuximab vedotin: 2 illustrative cases. Clin Lymphoma Myeloma Leuk. 2013;13:319–323.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Derenzini E, Pellegrini C, et al. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. Clin Lymphoma Myeloma Leuk. 2013;13:493–495.
   PubMed Web of Science ®Google Scholar
• Saintes C, Saint-Jean M, Renaut JJ, et al. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression. Br J Dermatol. 2015;172:819–821.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33:3750–3758.
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759–3765.
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;6736:31266–31267.
   Google Scholar
• Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401–409.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep. 2012;7:235–240.
   PubMed Web of Science ®Google Scholar
• Sugaya M, Morimura S, Suga H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol. 2015;42:613–615.
   PubMed Web of Science ®Google Scholar
• Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2015;21:274–285.
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. Expert Opin Drug Discov. 2014;9:467–483.
   PubMed Web of Science ®Google Scholar
• Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125:1883–1889.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–1163.
   PubMed Web of Science ®Google Scholar
• Shaw J, Kollnberger S. New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease. Front Immunol. 2012;3:339.
   PubMed Web of Science ®Google Scholar
• Bagot M, Moretta A, Sivori S, et al. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood. 2001;97:1388–1391.
   PubMed Web of Science ®Google Scholar
• Wechsler J, Bagot M, Nikolova M, et al. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes. J Pathol. 2003;199:77–83.
   PubMed Web of Science ®Google Scholar
• Poszepczynska-Guigné E, Schiavon V, D’Incan M, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol. 2004;122:820–823.
   PubMed Web of Science ®Google Scholar
• Bahler DW, Hartung L, Hill S, et al. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry. Cytometry B Clin Cytom. 2008;74:156–162.
   PubMed Web of Science ®Google Scholar
• Ortonne N, Le Gouvello S, Tabak R, et al. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides. Exp Dermatol. 2012;21:461–463.
   PubMed Web of Science ®Google Scholar
• Moins-Teisserenc H, Daubord M, Clave E, et al. CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J Invest Dermatol. 2015;135:247–257.
   PubMed Web of Science ®Google Scholar
• Marie-Cardine A, Viaud N, Thonnart N, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014;74:6060–6070.
   PubMed Web of Science ®Google Scholar
• Sicard H, Bonnafous C, Morel A, et al. A novel targeted immunotherapy for CTCL is on its way: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology. 2015;4:e1022306.
   PubMed Web of Science ®Google Scholar
• Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47:765–779.
   PubMed Web of Science ®Google Scholar
• Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125:3377–3383.
   PubMed Web of Science ®Google Scholar
• Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016;21:448–455.
   PubMed Web of Science ®Google Scholar
• Lonberg N, Korman AJ. Masterful antibodies: checkpoint blockade. Cancer Immunol Res. 2017;5:275–281.
   PubMed Web of Science ®Google Scholar
• Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015;27:3–10.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21:462–473.
   PubMed Web of Science ®Google Scholar
• Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146:1382–1388.
   PubMedGoogle Scholar
• Kantekure K, Yang Y, Raghunath P, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol. 2012;34:126–128.
   PubMed Web of Science ®Google Scholar
• Ravichandran KS, Collins TL, Burakoff SJ. CD4 and signal transduction. Curr Top Microbiol Immunol. 1996;205:47–62.
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–771.
   PubMed Web of Science ®Google Scholar
• Assaf C, Sterry W. Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4. Curr Opin Mol Ther. 2007;9:197–203.
   PubMed Web of Science ®Google Scholar
• Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4+ T cells in human skin by zanolimumab. Arch Dermatol Res. 2007;298:449–455.
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109:4655–4662.
   PubMed Web of Science ®Google Scholar
• Mestel DS, Beyer M, Mobs M, et al. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sezary syndrome. Expert Opin Biol Ther. 2008;8:1929–1939.
   PubMed Web of Science ®Google Scholar
• Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4:117ra7.
   PubMed Web of Science ®Google Scholar
• Ishida T, Ito A, Sato F, et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci. 2013;104:647.
   PubMed Web of Science ®Google Scholar
• Honda T, Hishizawa M, Kataoka TR, et al. Stevens-Johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient. Acta Derm Venereol. 2015;95:606–607.
   PubMed Web of Science ®Google Scholar
• Bliss-Moreau M, Coarfa C, Xiao W, et al. Synergy of small-molecule inhibitors in cutaneous T-cell lymphoma cells: a discovery tool to define new therapeutic targets in T-cell receptor (TCR) signaling pathways. Blood. 2013;122:4327.
   Google Scholar
• Debnath B, Xu S, Grande F, et al. Small molecule inhibitors of CXCR4. Theranostics. 2013;3:47–75.
   PubMed Web of Science ®Google Scholar
• Van Hout A, D’huys T, Oeyen M, et al. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 2017;12:e0176057.
   PubMed Web of Science ®Google Scholar
• Zhan MM, Hu XQ, Liu XX, et al. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov Today. 2016;21:1027–1036.
   PubMed Web of Science ®Google Scholar